CytomX Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CytomX Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $253.00K.
- CytomX Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2023-06-30 was $26.00K, a 71.43% decline year-over-year.
- CytomX Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-06-30 was $91.00K, a 47.40% decline year-over-year.
- CytomX Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2022-03-31 was $7.00K, a 99.32% decline year-over-year.
- CytomX Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.43M, a 70.71% decline from fiscal 2020.
- CytomX Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $4.88M, a 670.30% increase from fiscal 2019.
- CytomX Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $633.00K, a 84.77% decline from fiscal 2018.
- CytomX Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2018 was $4.16M, a 31.31% increase from fiscal 2017.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-09-30 | $253.00K 10-Q · filed 2025-11-06 | |
| 2023-06-30 | $26.00K 10-Q · filed 2024-11-07 | |
| 2022-06-30 | $91.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $7.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $1.43M 10-K/A · filed 2023-03-27 | |
| 2021-09-30 | $104.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $173.00K 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $1.02M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $4.88M 10-K/A · filed 2023-03-27 | |
| 2020-09-30 | $167.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.18M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $2.16M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $633.00K 10-K/A · filed 2023-03-27 | |
| 2019-09-30 | $63.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $33.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $465.00K 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $4.16M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $981.00K 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $366.00K 10-Q · filed 2019-11-07 | |
| 2018-03-31 | $2.60M 10-Q · filed 2019-11-07 | |
| 2017-12-31 | $3.17M 10-K · filed 2020-02-27 | |
| 2016-12-31 | $643.00K 10-K · filed 2019-02-27 | |
| 2015-12-31 | $263.00K 10-K · filed 2018-03-07 | |
| 2014-12-31 | $8.00K 10-K · filed 2017-03-02 | |
| 2013-12-31 | $60.00K 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |